Stock HUMA HUMACYTE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Humacyte, Inc.

Equities

HUMA

US44486Q1031

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
7.48 USD -17.80% Intraday chart for Humacyte, Inc. +4.62% +163.38%
May. 30 Certain Common Stock of Humacyte, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2024. CI
May. 30 Certain Warrants of Humacyte, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2024. CI

Evolution of the average Target Price on Humacyte, Inc.

Price target over the last 5 years

History of analyst recommendation changes

53ec3fd2c98e525.Dp5hoyXMlPGI48x7a4tX49A_re06fTRuq99DiBp7YCo.PMwmyhCCxbvEh5scP8MNtbhO24VvPn4ZyekKw3s1KmY58gz3VPT3mr609A~8816f2d8242710b98c700e1958ece4db

Analyst Recommendations on Humacyte, Inc.

Piper Sandler Adjusts Price Target on Humacyte to $4 From $3, Maintains Neutral Rating MT
HC Wainwright Initiates Humacyte With Buy Rating, Price Target is $6 MT
Humacyte, Inc. Announces Publication of Biological Mechanism Explaining Low Rates of Infection Observed in Clinical Study of Human Acellular Vessel CI
Cantor Fitzgerald Initiates Humacyte at Overweight Rating With $6 Price Target MT
BTIG Adjusts Humacyte's Price Target to $10 from $12, Keeps Buy Rating MT
Piper Sandler Double Downgrades Humacyte to Underweight From Overweight, Adjusts Price Target to $4 From $10 MT
Cowen Starts Humacyte at Outperform With $17 Price Target MT
HUMACYTE : Oppenheimer Starts Humacyte at Outperform with $16 Price Target MT
HUMACYTE : BTIG Starts Humacyte at Buy with $19 Price Target MT
HUMACYTE : Piper Sandler Starts Humacyte at Overweight With $17 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
7.48 USD
Average target price
8 USD
Spread / Average Target
+6.95%
High Price Target
15 USD
Spread / Highest target
+100.53%
Low Price Target
6 USD
Spread / Lowest Target
-19.79%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Humacyte, Inc.

Piper Sandler
HC Wainwright
Cantor Fitzgerald
BTIG
Cowen
Oppenheimer

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. HUMA Stock
  4. Consensus Humacyte, Inc.